Self-help Lifestyle Medicine for Generalized Anxiety Symptoms

March 4, 2022 updated by: Fiona YY Ho, Chinese University of Hong Kong

Smartphone-Delivered Lifestyle Medicine Intervention for Generalized Anxiety Symptoms: A Randomized Controlled Trial

This study will examine the effects of smartphone-based lifestyle medicine for alleviating generalised anxiety symptoms in Chinese population. Since a range of lifestyle factors are involved in the pathogenesis and progression of generalised anxiety disorder ( Cox & Olatunji, 2016; Dale et al., 2014; Vøllestad et al., 2012), modifying different lifestyle factors simultaneously, for examples, diet, exercise, stress and sleep, may be effective to reduce generalised anxiety symptoms. Recent studies indicate that service users are showing an increasing interest in self-help interventions for common mental disorders because of their accessibility and low cost (Marshall et al., 2021; Weisel et al., 2019). Nonetheless, to date, only limited self-help interventions that target lifestyle medicine for generalised anxiety symptoms are available.

This study will be a randomised controlled trial on the effects of a self-help smartphone-based lifestyle medicine intervention for reducing generalised anxiety symptoms in Chinese population. Prior to all study procedures, eligible participants will be required to complete an online informed consent (with telephone support). Around 50 eligible participants will be randomly assigned to either smartphone-based lifestyle medicine (LM group) or the waitlist control group (WL group) in a ratio of 1:1. The randomization will be performed by an independent assessor using a computer-generated list of numbers. Participants in the LM group will receive the multicomponent lifestyle medicine intervention via the app for 8 weeks, whilst the WL control group will receive the intervention after trial completion. The primary outcomes will be the level of generalised anxiety symptoms at immediate and 3-month post-intervention assessments; while the secondary outcomes will be the level of depressive symptoms, insomnia symptoms, physical activity, health-related quality of life, functional impairment, health-promoting behaviours, and intervention acceptability at immediate and 3-month post-intervention assessments.

Study Overview

Status

Not yet recruiting

Intervention / Treatment

Study Type

Interventional

Enrollment (Anticipated)

50

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Sha Tin, Hong Kong
        • The Chinese University of Hong Kong

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Hong Kong residents
  • Aged ≥ 18 years
  • Have a Generalized Anxiety Disorder-7 (GAD-7) score ≥ 8
  • Able to read Chinese and type in Chinese or English
  • Have an Internet-enabled mobile device (iOS or Android operating system)
  • Willing to provide informed consent and comply with the trial protocol

Exclusion Criteria:

  • Current involvement in psychotherapy or recent changes in medication for anxiety
  • A Patient Health Questionnaire-9 (PHQ-9) item 9 score > 2, indicating a serious level of suicidal risk (referral information to professional mental health services will be provided)
  • Self-disclosure of having unsafe health conditions for which physical activity or a change in diet was contraindicated by physicians
  • Self-disclosure of a diagnosis of any major psychiatric, medical or neurocognitive disorders that make participation unsuitable or that may interfere with the adherence to the lifestyle modifications

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Lifestyle Medicine Group
Lifestyle medicine smartphone app The lifestyle medicine app contains eight weekly modules that cover healthy eating, exercise, stress management, sleep management, lifestyle psychoeducation, and goal setting.
A smartphone-delivered application with a series of lifestyle medicine components, including lifestyle psychoeducational, physical activity, dietary recommendations, stress management, sleep management, and motivation and goal-setting techniques.
No Intervention: Waitlist Control Group
The waitlist control group will receive access to the lifestyle medicine app at the end of the study.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in the Generalized Anxiety Disorder-7 (GAD-7)
Time Frame: Baseline, immediate post-intervention, and 3-month post-intervention
GAD-7 is a seven-item scale for assessing the level of generalized anxiety in the past two weeks. It comprises questions related to feelings of anxious and worry in daily lives. This four-point Likert scale is rated from 0 (not at all) to 3 (almost everyday), and the cut off score on the sum of each item will be the standard to differentiate the anxiety level (5, 10, 15 correspond to mild, moderate and severe respectively)
Baseline, immediate post-intervention, and 3-month post-intervention

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in the Patient Health Questionnaire (PHQ-9)
Time Frame: Baseline, immediate post-intervention, and 3-month post-intervention
PHQ-9 is a nine-item scale for assessing the level of depressive symptoms in the past two weeks. This four-point Likert scale is rated from 0 (not at all) to 3 (almost every day), and the cut off scores on the sum of each item will be the standard to differentiate the depressive level (5, 10, 15, 20 correspond to mild, moderate, moderately severe and severe respectively)
Baseline, immediate post-intervention, and 3-month post-intervention
Change in the Insomnia Severity Index (ISI)
Time Frame: Baseline, immediate post-intervention, and 3-month post-intervention
ISI is a seven-item scale for measuring the severity of sleep disturbance. This five-point Likert scale is rated from 0 to 4 for each item, and a higher total score indicates the more severe of the insomnia condition (8, 15, 22 correspond to subthreshold insomnia, moderate clinical insomnia and severe clinical insomnia respectively).
Baseline, immediate post-intervention, and 3-month post-intervention
Change in the Short Form (Six-Dimension) Health Survey (SF-6D)
Time Frame: Baseline, immediate post-intervention, and 3-month post-intervention
SF-6D is a single index and preference-based questionnaire for measuring individual's quality of lives in the following six domains, including physical functioning, role limitation, social functioning, bodily pain, mental health, and vitality.
Baseline, immediate post-intervention, and 3-month post-intervention
Change in the Health-Promoting Lifestyle Profile (HPLP II)
Time Frame: Baseline, immediate post-intervention, and 3-month post-intervention
HPLP-II is a 52-item questionnaire for measuring the present lifestyle or personal habits with six sub-scale domains, including health responsibility, physical activity, nutrition, spiritual growth, interpersonal relations, and stress management. The inventory uses a four-point Likert scale, from 1 (never) to 4 (routinely), to evaluate the frequency of items asked to the participants.
Baseline, immediate post-intervention, and 3-month post-intervention
Change in the Sheehan Disability Scale (SDS)
Time Frame: Baseline, immediate post-intervention, and 3-month post-intervention
SDS is a three-item, self-reported 10-point visual analog scale on measuring one's severity level of impairment on three dimensions, including work/school, social life, and family life.
Baseline, immediate post-intervention, and 3-month post-intervention
Change in the Credibility-Expectancy Questionnaire (CEQ)
Time Frame: Baseline and immediate post-intervention
CEQ is a self-reported 6-item inventory for assessing one's attitude towards the credibility and expectancy of the intervention contents.
Baseline and immediate post-intervention
Change in the Treatment Acceptance Questionnaire (TAQ)
Time Frame: Baseline and immediate post-intervention
TAQ is a self-reported, six-item questionnaire that is rated by a seven-point Likert scale from 1 to 7, and it aims at evaluating the clients' attitude toward the treatment sessions by six domains, including acceptability, ethics, effectiveness, negative side effects, the therapist's knowledge, and the therapist's trustworthiness.
Baseline and immediate post-intervention
Change in the International Physical Activities Questionnaire-Chinese version (IPAQ-C)
Time Frame: Baseline, immediate post-intervention, and 3-month post-intervention
IPAQ-C is a 5-item questionnaire that measures the amount of sitting time, walking time, and moderate and vigorous exercise during the last 7 days. Different exercise types are categorized and rated as different metabolic equivalent tasks, while a higher score of the sum of total items represents a higher intense of activity level.
Baseline, immediate post-intervention, and 3-month post-intervention

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

June 1, 2022

Primary Completion (Anticipated)

December 1, 2022

Study Completion (Anticipated)

September 1, 2023

Study Registration Dates

First Submitted

March 4, 2022

First Submitted That Met QC Criteria

March 4, 2022

First Posted (Actual)

March 14, 2022

Study Record Updates

Last Update Posted (Actual)

March 14, 2022

Last Update Submitted That Met QC Criteria

March 4, 2022

Last Verified

March 1, 2022

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Generalised Anxiety Disorder

Clinical Trials on Lifestyle Medicine

3
Subscribe